Clinical trials are not short of risk signals. Study teams can now see query trends, site delays, enrollment gaps, protocol deviations, reconciliation issues, and monitoring alerts earlier than before.
The harder problem is what happens next.
That is the clinical trial execution gap: the breakdown between identifying a trial risk and converting it into coordinated, timely, documented action across sponsors, CROs, sites, vendors, and functional teams.
The urgency to address this gap is growing. As protocol complexity increases, development timelines lengthen, and R&D investments continue to rise, sponsors and CROs need more than visibility. The ability to convert risk signals into timely, coordinated action is becoming a critical operational capability.
In an Applied Clinical Trials article, Kenneth Getz and Kenneth Kaitin define the Clinical Execution Translation Gap as the failure to convert identified problems in clinical development into coordinated and timely action. This shifts the discussion away from visibility alone and toward the operating discipline required after a signal appears.
For clinical operations, data management, QA, regulatory, and executive teams, this distinction matters. A signal does not resolve a delayed site follow-up. A dashboard does not clear a query backlog. A risk report does not complete root cause analysis or confirm whether a corrective action worked.
What lies ahead in clinical trial execution is a shift from passive monitoring to governed action paths. That is the model Maxis AI has started delivering: turning operational signals into supervised, traceable execution without removing human accountability.
What is the clinical trial execution gap?
The risks in a clinical trial and converting those risks into coordinated, timely, and documented action across trial stakeholders.
Why Clinical Trial Execution Is Becoming Harder
Clinical trial execution is becoming harder because study design and delivery models have become more complex. Modern protocols often involve more endpoints, eligibility criteria, procedures, countries, investigative sites, and data points than earlier trial designs.
A Tufts CSDD study published in Therapeutic Innovation & Regulatory Science found that Phase II and Phase III protocols continue to show an upward trend across major design variables, including endpoints, protocol pages, investigative sites, countries, and data points collected. Read the study summary.
More Complexity Creates More Handoffs
For sponsors and CROs, complexity does not stay on paper. It becomes operational workload.
More sites mean more startup coordination. More procedures mean more source data and monitoring burden. More data points mean more cleaning, reconciliation, and review. More vendors mean more handoffs across clinical operations, data management, safety, QA, regulatory, and biometrics.
That is why the execution gap is expanding. Trial teams may receive signals earlier, but each signal still needs ownership, escalation, follow-up, documentation, and confirmation that the issue has been resolved.
Why Detection Alone Does Not Close the Gap
Better monitoring has helped clinical teams identify risks earlier. But detection does not decide ownership, trigger follow-up, document corrective action, or confirm whether the issue has been resolved.
The Applied Clinical Trials article makes this point directly: the execution translation gap is not mainly a knowledge gap. It is a failure to execute clinical activity efficiently and effectively once problems are known.
A 2024 Tufts CSDD study on risk-based quality management adoption also shows why this matters. While RBQM is designed to improve trial quality by prioritizing important risks, adoption barriers include poor change management, mixed perceptions of value, and limited organizational readiness.
Signals Still Need an Operating Path
Once a risk signal appears, the study team still needs to answer:
Who owns the next action?
What timeline applies?
Which function needs to respond?
What requires escalation?
What must be documented?
How will recurrence be tracked?
As Kenneth Getz noted during the webinar, the industry has become highly effective at generating insights, dashboards, and risk signals. However, many organizations still rely on email chains, spreadsheets, meetings, and manual coordination to determine ownership and next actions. This creates a growing disconnect between visibility and execution.
More visibility does not automatically create better execution. Clinical trial teams need governed action paths that turn signals into accountable work.
This is the practical center of the clinical trial execution gap. Risk signals are useful only when they move into a clear execution path with ownership, timing, review, documentation, and follow-through.
The Evidence Behind the Clinical Trial Execution Gap
The execution problem is now visible in trial performance data. Risks are being detected, but resolution still moves too slowly across many studies.
Several public benchmarks show why this gap is becoming harder to ignore:
- A Tufts CSDD working group study found that Phase II and Phase III protocols had a mean total of 75 and 119 protocol deviations, respectively, with deviations involving nearly one-third of enrolled patients. Read the protocol deviation study.
- A Tufts CSDD protocol amendment study reported that the time from identifying the need to amend to final oversight approval now averages 260 days, while sites operate with different protocol versions for a mean of 215 days. Read the protocol amendment study.
- A 2024 analysis by Smith, DiMasi, and Getz estimated that a single day of development delay equals approximately $500,000 in lost prescription drug or biologic sales. Read the delay-day study.
Operational Delays Become Economic Risk
For clinical operations and executive teams, these numbers point to the same issue: unresolved signals have business consequences.
A deviation is not only a quality event. An amendment is not only a document update. A delayed escalation is not only a workflow issue. Each can affect patient enrollment, site burden, database lock, submission readiness, and portfolio-level forecast confidence.
That is why the gap cannot be solved by monitoring alone. The next step is to reduce the time between signal, ownership, action, and documented resolution.
Clinical Trial Execution Steps: Moving From Signal to Action
Closing the gap requires a clear operating path after a risk signal appears. This is where clinical trial execution steps become important. A signal should not sit in a dashboard, tracker, or meeting note without a defined next action.
A practical execution path should include:
- Detect the operational signal
- Classify the risk and its potential impact
- Define the response threshold
- Assign the functional owner
- Trigger the required action path
- Set the escalation timeline
- Apply human review where needed
- Document the action and decision trail
- Track whether the issue was resolved
- Monitor recurrence across sites or studies
Why Action Paths Matter
Action paths reduce ambiguity. They help study teams move from “this is a risk” to “this is the next governed step.”
This is consistent with the direction of ICH E6(R3), which reinforces risk-based quality management, proportionate controls, sponsor oversight, and documented trial conduct.
For sponsors and CROs, the goal is not only faster response. The goal is controlled response: the right owner, the right workflow, the right review point, and the right documentation.
Execution Risk Indicators: Measuring Response, Not Just Risk
Risk indicators help clinical trial teams detect potential issues. Execution Risk Indicators, or ERIs, go one step further.
ERIs measure whether the response to a risk is happening fast enough, with the right owner, timeline, escalation path, and follow-through.
This distinction matters because many clinical trial teams already have visibility into risk. They can see query delays, site activation issues, protocol deviations, amendment delays, reconciliation gaps, and vendor follow-up problems. The execution gap begins when those signals do not move into timely, coordinated, and documented action.
What Are Execution Risk Indicators?
Traditional Key Risk Indicators, or KRIs, help teams understand whether a risk exists. ERIs help teams understand whether the organization is responding to that risk with enough speed, ownership, and control.
In simple terms:
KRIs ask: Is there a risk?
ERIs ask: Is the risk being acted on quickly and effectively?
For example, a KRI may show that eCRF data entry is delayed at a site. An ERI would measure how long it took to assign ownership, initiate follow-up, escalate the delay if needed, and confirm that the issue was resolved.
This is why ERIs are important to the clinical trial execution gap. They do not only measure risk exposure. They measure response quality.
Examples of ERIs in Clinical Trial Execution
The Applied Clinical Trials article recommends defining Execution Risk Indicators upfront so trial teams can measure how well risks are being converted into action.
Examples of ERIs may include:
- Time to resolve data quality issues
- Time to implement protocol amendments
- Deviation recurrence rates
- Site activation timelines
- Time from risk signal detection to owner assignment
- Time from threshold breach to escalation
- Time from query backlog identification to closure plan
- Time from vendor delay identification to documented follow-up
- Percentage of recurring issues with completed root cause review
- Percentage of action items closed within the defined timeline
These examples show why ERIs are different from standard operational metrics. They are not only asking whether something went wrong. They are asking whether the response was timely, owned, documented, and effective.
From Risk Thresholds to Action
This builds on the same logic used in risk-based monitoring. Thresholds define when a risk indicator should trigger action. Those actions may include remote review, site follow-up, immediate investigation, escalation, or corrective action.
The execution issue is what happens after the threshold is crossed.
For example:
- A data quality issue should not only raise an alert. It should trigger ownership, follow-up, and closure tracking.
- A recurring deviation should not only be logged. It should trigger root cause review and corrective action.
- A site activation delay should not only appear in a tracker. It should trigger escalation against a defined timeline.
A vendor delay should not only be discussed in a meeting. It should trigger documented follow-up, accountability, and resolution tracking.
This matters because risk-signal closure itself can be slow. In one Applied Clinical Trials industry trends analysis, research organizations took an average of 35 days to process and close each risk signal.
Execution Risk Indicators help close that loop. They move the focus from “Did we detect the risk?” to “Did we act on it fast enough, with the right owner, and did the action resolve the issue?”
This is the bridge between risk detection and governed execution. Once ERIs are defined, clinical trial teams can move into a structured execution methodology: assess the signal, define thresholds, assign ownership, govern the response, and measure whether action paths are improving resolution over time.
A Clinical Trial Execution Methodology for Governed Action
A clinical trial execution methodology should define what happens after a risk signal appears. It should not leave action to informal follow-ups, meeting notes, or disconnected trackers.
A practical model can follow four steps:
1. Assess and Prioritize
Identify where delays repeat most often. Common areas include query aging, site activation, reconciliation lag, recurring deviations, amendment implementation, and vendor follow-up.
2. Define Thresholds and Action Paths
Set clear thresholds for when a signal becomes an execution risk. Then define the required action path: owner, timeline, escalation point, documentation, and review step.
This aligns with ICH E6(R3), which advances risk-based quality management, proportionate controls, sponsor oversight, and documented trial conduct. ICH E8(R1) also reinforces the need to focus study design and execution on critical-to-quality factors
3. Govern the Response
Every action path should preserve human accountability. Sensitive actions need review, approval, and traceable documentation before execution.
4. Measure and Improve
Track whether action paths reduce time-to-resolution, recurring deviations, unresolved queries, and avoidable escalations.
What is a clinical trial execution methodology?
A clinical trial execution methodology is a structured approach for turning trial risks into governed action through defined thresholds, assigned owners, escalation rules, human review, documentation, and continuous measurement.
Why AI-Guided Action Paths Matter Now
AI-guided action paths matter because clinical trial teams are being asked to manage more risk signals without adding proportional execution capacity.
In the current model, many signals still move through manual coordination:
- A risk is detected.
- The issue is discussed in meetings.
- Follow-up is assigned through email or trackers.
- Escalation depends on individual judgment.
- Documentation is completed after the fact.
That model is difficult to scale across large portfolios, outsourced studies, and multi-vendor delivery environments.
A guided action path creates a more disciplined route from signal to response. When a threshold is crossed, the workflow can define the next step, assign the right owner, set the timeline, route the review, and preserve the decision trail.
The webinar described this shift as moving from a “Detect and Delegate” model to a “Detect, Guide, and Execute” model. In traditional workflows, teams identify issues but must manually determine ownership, communication paths, escalation requirements, and documentation activities. AI-guided action paths help standardize these next steps, reducing coordination effort while maintaining appropriate human oversight.
This direction also fits the regulatory shift toward proactive, risk-based oversight. ICH E6(R3) emphasizes quality by design, proportionate risk management, sponsor oversight, and documented trial conduct. The FDA’s draft guidance on protocol deviations also reinforces the need for clearer identification, classification, documentation, and reporting of deviations.
The point is not to remove clinical judgment. The point is to reduce coordination drag so clinical teams can spend more time on review, decisions, and risk resolution.
How Maxis AI Is Already Delivering This Operating Model
The next operating model for clinical trials is not another layer of passive oversight. It is governed execution: the ability to move from signal to action with clear ownership, human review, and traceable follow-through.
Maxis AI enables this shift through an Agentic AI operating model designed specifically for regulated clinical environments. The platform combines specialized AI agents, configurable execution risk indicators, governed action paths, and human-in-the-loop controls to help sponsors and CROs move from detection to action more efficiently.
The model is designed to work within existing clinical systems rather than replace them. This matters for sponsors and CROs that already rely on EDC, CTMS, eTMF, RBQM, safety, lab, and reporting environments.
In practice, this means:
- Defined action paths after risk thresholds are crossed
- Human approval where judgment or accountability is required
- Documented activity for review and audit readiness
- Workflow support across high-volume operational tasks
- Scalable execution capacity without depending only on additional headcount
Maxis AI also brings domain depth from experience across 3,300+ clinical trials in the cloud, supporting the practical implementation of governed execution in regulated trial environments.
How can clinical trial teams move from risk signals to action?
Clinical trial teams can move from risk signals to action by defining thresholds, assigning owners, triggering guided action paths, applying human review, documenting decisions, and measuring whether the issue was resolved.
To explore this operating model in more depth, watch the on-demand webinar: AI-Guided Action Path to Address the Clinical Execution Translation Gap
The session examines:
- Why execution inefficiencies persist despite better trial visibility
- How Execution Risk Indicators help measure response quality
- How guided action paths can support timely follow-up and escalation
- Why human oversight remains central in regulated trial operations
- What clinical operations teams should consider as execution models evolve
Conclusion: Closing the Clinical Trial Execution Gap Requires Governed Execution
This execution gap is not caused by a lack of data, dashboards, or risk signals. It is caused by the difficulty of converting those signals into coordinated, timely, and documented action across complex trial environments.
For sponsors and CROs, the next step is not simply better monitoring. It is a more disciplined execution model built around thresholds, ownership, guided action paths, human review, and traceable resolution.
That is where clinical operations is heading: from detecting risk to resolving risk with governance.
To see how this model is taking shape, watch the on-demand webinar on AI-guided action paths and the Clinical Execution Translation Gap.
FAQs
The clinical trial execution gap is the breakdown between identifying operational risks in a trial and converting those risks into coordinated, timely, and documented action across sponsors, CROs, sites, vendors, and functional teams.
Risk signals often fail to become action because ownership is fragmented, escalation is manual, workflows are distributed across systems, and teams lack a governed path for moving from detection to resolution.
Clinical trial execution steps include protocol planning, startup, site activation, enrollment, monitoring, data management, issue resolution, safety oversight, database lock, analysis, and reporting.
Common causes include complex protocol designs, slow startup, fragmented accountability, delayed vendor handoffs, protocol deviations, amendment implementation delays, data reconciliation issues, and unclear escalation paths.
Execution Risk Indicators are metrics that measure whether teams are responding to trial risks quickly and effectively. They are metrics that measure the effectiveness of operational response after a risk signal appears. Examples include time-to-resolve data issues, amendment implementation time, deviation recurrence, and site activation timelines.
Key Risk Indicators help detect risk. Execution Risk Indicators measure whether the response to that risk is timely, coordinated, and effective enough to prevent recurrence or operational delay.
Risk-based quality management supports clinical trial execution by focusing oversight on critical risks, quality factors, and data integrity. It helps teams prioritize issues, define controls, and maintain documented trial conduct.
Guided action paths improve clinical trial execution by turning risk thresholds into assigned actions, timelines, escalation steps, human review points, and documented resolution workflows.
An AI-guided action path is a structured workflow that helps convert risk signals into governed actions by assigning ownership, defining timelines, triggering escalation steps, supporting documentation, and maintaining human oversight throughout the resolution process.
